

Iron Deficiency Anemia (IDA)

Inpatient

Concern for iron deficiency anemia based on history, physical exam, or prior labs

Inclusion Criteria

- ≥ 6 months of age with history, symptoms or laboratory findings concerning for IDA
- Admitted patients incidentally noted to have IDA

Exclusion Criteria

- Active Bleeding
- Traumatic etiology for blood loss
- Anemia related to chronic disease (e.g. oncologic, inflammatory, gastrointestinal)
- Inflammatory bowel disease

Active vaginal bleeding or anemia due to abnormal uterine bleeding?

Yes

Off Pathway
[See Abnormal Uterine Bleeding Pathway](#)

No

If not already obtained, collect labs

- Consider IV placement - *Place away from flexible joints if possible*
- Type and screen if hypotensive or ill appearing requiring transfusion
- CBC w/ Diff (if > 24 hours since last value)
- Reticulocytes
- CMP*
- Phosphorous**
- Iron w/ Total Iron Binding Capacity (TIBC)
- Ferritin
- Consider Soluble transferrin receptor***

* If edema/concern for associated protein losing enteropathy
** helpful to determine type of infusion
***identifies IDA cause by anemia of chronic disease/ inflammation

[Definitions](#)

[Risk Factors](#)

[Clinical History](#)

[Infusion Reactions](#)

[Lab results indicating anemia due to iron deficiency?](#)

Yes

No

Off Pathway
[Consider Differential Diagnosis](#)

[Symptomatic Anemia](#) or hemoglobin ≤ 4?

Yes

Hematology consult

No

Hemoglobin ≥ 6.1?

Yes

Hemoglobin 4.1 – 6.0?

Yes

[Oral iron supplementation](#)
Follow-up with PCP in 1 week, consider Hematology follow-up for [follow-up labs](#)

Consult Hematology

[Administer IV iron](#)

- [IV Iron Discharge Instructions](#)
- [Oral iron supplementation](#)
- Follow up in 1 week with hematology for [follow-up labs and possible repeat iron infusion](#)

Any of the following?

- Hgb < 3
- Hypotension

Yes

Call ACT. Consider transfer to ICU.

Initiate transfusion of RBCs 5 mL/kg (not to exceed 1 unit)
Run slowly over 3 hours

If transferred to the ICU, transfer to the floor when vitals stable and symptoms improve.

[Administer IV iron](#)

[Symptomatic anemia](#), Hypoxia, acute respiratory failure?

Yes

No

Definitions

Anemia: Hemoglobin value below the 2.5% for age and biological gender, as per institutionally established laboratory standards (See table below – the lower end of the range represents the 2.5%)

Symptomatic Anemia: presence of one or more of the following symptoms with laboratory confirmed anemia:

- Hypoxemia, shortness of breath
- Acute respiratory failure
- Hypotension
- Positive orthostatic vital signs
- Sustained tachycardia
 - To meet the definition of symptomatic, tachycardia should be observed in a calm and resting child
 - Age-appropriate values for heart rate should be used in assessment

Asymptomatic Anemia: No evidence of any of the above noted symptoms

Test Name	Units	Age Range	Normal Range Male	Normal Range Female
Hemoglobin	g/dL	6M to <2Y	10.5-13.5	10.5-13.5
Hemoglobin	g/dL	2Y to <6Y	11.5-13.5	11.5-13.5
Hemoglobin	g/dL	6Y to <12Y	11.5-15.5	11.5-15.5
Hemoglobin	g/dL	12Y to <15Y	12.5-16.4	12.0-16.0
Hemoglobin	g/dL	15Y to <18Y	13.1-16.9	12.0-16.0

[Return to Algorithm](#)

Risk Factors

- Excessive ingestion of cow's milk (> 24 oz of milk daily)
- Obesity
- Restrictive diets
- Menorrhagia
- Inflammatory Bowel Disease
- Severe and frequent epistaxis
- Gastrointestinal bleeding

[Return to Algorithm](#)

Clinical History

- Fatigue
- Pallor (palmar creases, evaluate conjunctiva, oral mucosa and nail beds)
- Lethargy
- Poor feeding
- Cardiomegaly
- Pica

[Return to Algorithm](#)

Differential Diagnosis of Anemia

- Acute blood loss anemia
- Hemolytic anemia
- Thalassemia
- Viral suppression
- Leukemia
- Lead poisoning
- Renal Disease
- Hypothyroidism

[Return to Algorithm](#)

Laboratory Results Indicative of IDA

- Hemoglobin (HGB) < 2.5% for age and gender (lower number in range on table below)
- MCV < 80
- Low:
 - Iron
 - Transferrin Saturation
 - Ferritin
- High
 - Total Binding Iron Capacity (TIBC)
 - RDW

Test Name	Units	Age Range	Normal Range Male	Normal Range Female
Hemoglobin	g/dL	6M to <2Y	10.5-13.5	10.5-13.5
Hemoglobin	g/dL	2Y to <6Y	11.5-13.5	11.5-13.5
Hemoglobin	g/dL	6Y to <12Y	11.5-15.5	11.5-15.5
Hemoglobin	g/dL	12Y to <15Y	12.5-16.4	12.0-16.0
Hemoglobin	g/dL	15Y to <18Y	13.1-16.9	12.0-16.0

[Return to Algorithm](#)

Ferric Carboxymaltose/Injectafer™

- Indications for Ferric Carboxymaltose (FCM):
 - Age ≥ 1 year
 - Previous laboratory assessment and clinical evaluation consistent with iron deficiency anemia
 - Patient is not a candidate for oral iron, or has failed oral iron therapy, or has hgb < 6
- If able, obtain phosphorous level prior to administration of FCM
 - This will be followed up as outpatient and does not need to be resulted prior to giving the FCM.
 - If unable to obtain phosphorous level, appropriate to proceed with FCM infusion
 - If level is normal, appropriate to proceed with FCM infusion
 - If level is low, appropriate to proceed with FCM infusion, or alter therapy in discussion with heme-onc
 - Clinicians can transition therapy to [iron sucrose](#) (often preferred by insurance), however, this therapy will likely require an increased number of dose administrations and IV placements
 - Risks and benefits for both infusions should be discussed with patient and family, and arrive at therapy option through shared decision making

- Peripheral IV placement
 - IV placement must be away from joints and/or “bends”
 - This is not a contraindication to giving the infusion if no other IV sites can be obtained
 - Utilize arm immobilization devices
 - Instruct patients to keep arm straight and instruct patients/parents to notify RN if patient is experiencing pain during the infusion.
 - FCM may be administered through central venous access if present
- FCM administration instructions
 - Infusion will be run via pump for 20 minutes
 - FCM is ordered as 15mg/kg, with maximum one-time infusion dose of 750mg
 - Vital signs to be measured at baseline, 5 minutes into the infusion, at the completion of the infusion, and at completion of observation period
 - Post-infusion 10mL flush will be administered
 - Patients should be observed for a 30-minute observation period, to evaluate for [hypersensitivity reactions](#)

[Return to Algorithm](#)

Iron Sucrose/Venofer™

Please note: Iron sucrose should only be used for patients <1 year old; or low phosphorus; AND in direct consultation/recommendation by Hematology; otherwise FCM is preferred therapy

Age	Dose
≥ 6 months – 17 years	Initial dose: 7 mg/kg not to exceed 100 mg Maintenance dose: 7 mg/kg not to exceed 300 mg
≥ 18 years	Initial & Maintenance dose: 7 mg/kg not to exceed 300 mg

*Iron sucrose doses up to 100 mg: 15 minute infusion

*Iron sucrose doses between 100 mg - 300 mg: 60 minute infusion

[Return to Algorithm](#)

[Return to Infusion
Practice](#)

Discharge Criteria

- Discharge when symptoms are improved and hypoxia and hypotension have resolved
- Discharge is not dependent on hemoglobin level and determined on a case-by-case basis with involvement of hematology

Oral Iron Supplementation

Oral Iron Supplementation:


- If patient can swallow pills and is ≥ 35 kg:
 - Ferrous sulfate 325 mg (65 mg elemental iron) once per day x 3 months
 - If patient cannot swallow pills or are < 35 kg:
 - Fer-in-sol 3 mg/kg of elemental iron (max 100 mg elemental iron) once per day x 3 months
- OR**
- Novaferum liquid (polysaccharide-iron complex) 3 mg/kg of elemental iron (max 100 mg elemental iron) once per day x 3 months

Follow-up Labs & Recurrent FCM Infusion

- Laboratory Evaluation for moderate/severe anemia – 1-2 weeks
 - Hematological labs (CBC, Retic)
 - Repeat phosphorous level if low baseline phosphorus/FCM infusion
- Laboratory Evaluation – 12 weeks
 - Hematological Labs (CBC, Retic, Ferritin)
- Clinical determination if additional IV iron required
 - Additional IV iron, FCM or Iron Sucrose depending on insurance, should be given at least 7 days after administration of 1st dose

[Return to Algorithm](#)

Hypersensitivity Reactions



[Return to Algorithm](#)

Adapted from:
Rampton D, Foklensen J, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. *Hematologica*. 2014;99(11):1671-1676.

[Return to Infusion Practice](#)

References

1. O'Brien SH, Badawy SM, Rotz SJ, et al. The ASH-ASPPO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. *Blood Advances*. 2022;6(2):679-685. doi:<https://doi.org/10.1182/bloodadvances.2020003635>
2. Ning S, Zeller MP. Management of iron deficiency. *Hematology Am Soc Hematol Educ Program*. 2019;2019(1):315-322. doi:10.1182/hematology.2019000034
3. Toward Optimized Practice Iron Deficiency Anemia Committee. 2018 March. Iron deficiency anemia clinical practice guideline. Edmonton, AB: Toward Optimized Practice. Available from: <http://www.topalbertadoctors.org>
4. Scott LJ. Ferric Carboxymaltose: A Review in Iron Deficiency. *Drugs*. 2018;78(4):479-493. doi:10.1007/s40265-018-0885-7
5. Injecatfer [package insert]. Shirley, NY: American Regent, Inc.; November 2021.
6. Rampton D, Foklensen J, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. *Hematologica*;2014;99(11):1671-1676.
7. Powers JM, Heeney MM, Hord J, et al. Prevention, Screening, Diagnosis, and Treatment of Iron Deficiency and Iron Deficiency Anemia in Infants, Children, and Adolescents: Clinical Report. *Pediatrics*. 2026;158(1):e2026077414. doi:10.1542/peds.2026-077414

[Return to Algorithm](#)

Quality Measures

Goal: Appropriate evaluation and treatment of iron deficiency anemia that minimizes inappropriate blood transfusions and facilitates appropriate admissions to an inpatient unit, when indicated.

Process Metrics:

- Pathway visualization
- Order panel utilization

Outcome Metrics:

- Length of stay
- Blood transfusion rates

Balancing Measures:

- Return to the Emergency Department/Urgent Care for anemia related concern within 72 hours
- Iron infusion reactions

[Return to Algorithm](#)

Team & Process

Content Development Team

Leaders:

Hospital Medicine:

Sarah Marzec, MD, MA

Hematology & Oncology:

Amanda Jacobson-Kelly, MD, MSc

Vilmarie Rodriguez, MD

Members:

Hematology & Oncology:

Kathleen Nicol, MD

Andrew Picca, DO

Emergency Medicine:

Aarti Gaglani, MD

David Kling Jr, DO

Pharmacy:

Mara Crabtree, PharmD

Cassandra Rush, PharmD

Clinical Pathways Program:

Medical Director – Associate Chief Quality Officer, Center for Clinical Excellence:

Ryan Bode, MD, MBOE

Medical Director – Clinical Informatics & Emergency Medicine:

Laura Rust, MD, MPH

Business & Development Manager:

Rekha Voruganti, MBOE, LSSBB

Program Coordinator:

Tara Dinh, BS

Clinical Pathway Approved

Medical Director – Associate Chief Quality Officer, Center for Clinical Excellence:

Ryan Bode, MD, MBOE

Origination Date: *August, 2023*

Last Revision: *August, 2026*

Next Revision Date: *August, 2031*

Clinical Pathway Development

This clinical pathway was developed using the process described in the NCH Clinical Pathway Development Manual Version 6, 2022. Clinical Pathways at Nationwide Children's Hospital (NCH) are standards which provide general guidance to clinicians. Patient choice, clinician judgment, and other relevant factors in diagnosing and treating patients remain central to the selection of diagnostic tests and therapy. The ordering provider assumes all risks associated with care decisions. NCH assumes no responsibility for any adverse consequences, errors, or omissions that may arise from the use or reliance on these guidelines. NCH's clinical pathways are reviewed periodically for consistency with new evidence; however, new developments may not be represented, and NCH makes no guarantees, representations, or warranties with respect to the information provided in this clinical pathway.

Copyright © 2026. Nationwide Children's Hospital. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without the express written permission of Nationwide Children's Hospital.

**For more information about our pathways and program please contact:
ClinicalPathwaysProgram@NationwideChildrens.org**

[Return to Algorithm](#)